Saltar al contenido
Merck

A265

Sigma-Aldrich

ARL 67156 trisodium salt hydrate

≥98% (HPLC), solid, ecto-ATPase inhibitor

Sinónimos:

6-N,N-Diethyl-β-γ-dibromomethylene-D-adenosine-5′-triphosphate trisodium salt hydrate, FPL 67156

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C15H21Br2N5Na3O12P3 · xH2O
Número de CAS:
Peso molecular:
785.05 (anhydrous basis)
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

product name

ARL 67156 trisodium salt hydrate, ≥98% (HPLC), solid

Quality Level

assay

≥98% (HPLC)

form

solid

color

white to off-white

solubility

H2O: >20 mg/mL
DMSO: insoluble

storage temp.

−20°C

SMILES string

O.[Na+].[Na+].[Na+].CCN(CC)c1ncnc2n(cnc12)[C@@H]3O[C@H](COP(O)(=O)OP([O-])(=O)C(Br)(Br)P([O-])([O-])=O)[C@@H](O)[C@H]3O

InChI

1S/C15H24Br2N5O12P3.3Na.H2O/c1-3-21(4-2)12-9-13(19-6-18-12)22(7-20-9)14-11(24)10(23)8(33-14)5-32-37(30,31)34-36(28,29)15(16,17)35(25,26)27;;;;/h6-8,10-11,14,23-24H,3-5H2,1-2H3,(H,28,29)(H,30,31)(H2,25,26,27);;;;1H2/q;3*+1;/p-3/t8-,10-,11-,14-;;;;/m1..../s1

InChI key

UWMONIJVKGTUGE-OPKBHZIBSA-K

Gene Information

human ... ENTPD2(954)

General description

ARL 67156, a nucleotide/ATP analog is a competitive inhibitor of CD39. This ecto-ATPase inhibitor is presumed to be metabolically stable in biological studies due to its β, γ-dibromomethylene bridge.
ARL-67156 preferentially inhibits the degradation of ADP compared to the degradation of ATP in the murine colon. It is commonly employed to inhibit ATP hydrolysis in tissue preparations.

Application

ARL 67156 trisodium salt hydrate has been used:
  • to prevent ATP degradation during cerebrospinal fluid extraction
  • as an ATPase inhibitor in ATP quantification assay for preventing ATP degradation in cytoplasm and mitochondrion
  • as an ecto-ATPase inhibitor to treat cancer cells for ATP release assay

Biochem/physiol Actions

ecto-ATPase inhibitor; prevents metabolism of P2 purinoceptor agonists.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

T D Westfall et al.
European journal of pharmacology, 329(2-3), 169-173 (1997-06-25)
The influence of enzymatic degradation on the neurotransmitter actions of ATP was studied using the ecto-ATPase inhibitor 6-N,N-diethyl-D-beta,gamma-dibromomethyleneATP (ARL 67156). Field stimulation of the parasympathetic nerves innervating guinea-pig urinary bladder muscle strips (1-8 Hz for 20 s) produced characteristic biphasic
Charlie H T Kwok et al.
Frontiers in immunology, 12, 626884-626884 (2021-04-27)
Increased afferent input resulting from painful injury augments the activity of central nociceptive circuits via both neuron-neuron and neuron-glia interactions. Microglia, resident immune cells of the central nervous system (CNS), play a crucial role in the pathogenesis of chronic pain.
S A Lévesque et al.
British journal of pharmacology, 152(1), 141-150 (2007-07-03)
ARL 67156, 6-N,N-Diethyl-D-beta-gamma-dibromomethylene adenosine triphosphate, originally named FPL 67156, is the only commercially available inhibitor of ecto-ATPases. Since the first report on this molecule, various ectonucleotidases responsible for the hydrolysis of ATP at the cell surface have been cloned and
B E Crack et al.
British journal of pharmacology, 114(2), 475-481 (1995-01-01)
1. FPL 67156 (6-N,N-diethyl-beta, gamma-dibromomethylene-D-ATP), is a newly synthesized analogue of ATP. 2. In a rabbit isolated tracheal epithelium preparation, measuring P2U-purinoceptor-dependent chloride secretion, FPL 67156 was discovered to potentiate the responses to UTP but not those to ATP-gamma-S. UTP
Laura Schäkel et al.
Frontiers in pharmacology, 11, 1294-1294 (2020-10-06)
Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5'-nucleotidase (CD73) to immunosuppressive

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico